Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| PID2019-104167RB-I00 | Other Grant/Funding Number | MCIN/AEI/10.13039/501100011033 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hospital ClÃnico Universitario de Valencia | OTHER |
| University of Bologna | OTHER |
Not provided
Not provided
Not provided
Potential anti-eryptotic effect of a regular intake of a plant sterol (PS)-containing food supplement, in moderate hypercholesterolemic patients treated with the PS-containing food supplement or placebo supplement.
Oxidative damage has been related to the externalization of phosphatidylserine in erythrocytes, an event associated with eryptosis (programmed death of erythrocytes). In addition, an increase in eryptosis has been observed in patients with hypercholesterolaemia. PS-enriched food supplements could be a nutritional strategy to improve risk factors in patients with moderate hypercholesterolemia treated with statins, constituting a synergistic treatment with these drugs. The present study aims to evaluate the eryptotic process (externalization of phosphatidylserine) after regular intake of a food supplement containing PS (2g/day) in patients with moderate hypercholesterolemia treated with statins. This is a case-control study with 32 cases (intake or a PS-containing food supplement) and 16 controls (placebo intake based on the excipient), with an intervention period of 6 weeks. The evaluation of eryptosis is carried out by determining the externalization of phosphatidylserine, the size of the erythrocytes and an ex vivo assay of adhesion of eryptotic erythrocytes to the vascular endothelium. In addition, the redox state (GSH), the in vivo oxidation of cholesterol (COPs), and biochemical and hematological parameters are evaluated. All parameters are evaluated at the beginning (week 0) and at the end of the intervention period (week 6).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PS-containing dietary supplement | Experimental | Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day) |
|
| Placebo | Placebo Comparator | Sachet containing the excipients of the ingredient (2,25 g placebo/day) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PS-containing dietary supplement | Dietary Supplement | Sachet containing a powdered ingredient source of microencapsulated free plant sterols (2,25 g ingredient/day) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Changes in the externalization of phosphatidylserine | The externalization of phosphatidylserine, assessed by flow cytometry (Kit Annexin V) with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Changes in the adhesion to the endothelium by eryptotic erythrocytes | The adhesion to the endothelium by eryptotic erythrocytes, assessed with parallel-plate flow chamber technique in human umbilical vein endothelial cells (HUVECs) with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Changes in cell size ('forward scatter') | Cell size, assessed by flow cytometry with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Changes in reduced glutathione cellular levels (GSH) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Amparo Asunción AlegrÃa Torán, Professor | University of Valencia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital ClÃnico Universitario de Valencia | Valencia | Valencia | 46010 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34473881 | Background | Cilla A, Lopez-Garcia G, Collado-Diaz V, Amparo Blanch-Ruiz M, Garcia-Llatas G, Barbera R, Martinez-Cuesta MA, Real JT, Alvarez A, Martinez-Hervas S. Hypercholesterolemic patients have higher eryptosis and erythrocyte adhesion to human endothelium independently of statin therapy. Int J Clin Pract. 2021 Nov;75(11):e14771. doi: 10.1111/ijcp.14771. Epub 2021 Sep 7. | |
| 35328440 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D006937 | Hypercholesterolemia |
| D050197 | Atherosclerosis |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Other | Sachet containing the excipients of the ingredient (2,25 g placebo/day) |
|
GSH, assessed by flow cytometry (Green CMFDA), with repeated measures (at the beginning and at the end of the intervention)
| 0 and 6 weeks |
| Changes in plasmatic levels of cholesterol oxidation products (COPs) | COPs levels, assessed by gas chromatography-mass spectometry, with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Changes in plasmatic glucose | Glucose, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Changes in plasmatic total cholesterol | Total cholesterol, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Changes in plasmatic HDL-c | HDL-c, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Changes in plasmatic LDL-c | LDL-c, calculated by the Friedewald's formula, with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Changes in plasmatic triglycerides | Triglycerides, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Changes in plasmatic Apo A | Apo A, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Changes in plasmatic Apo B | Apo B, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Changes in plasmatic High-sensitivity C-reactive protein (hsCRP) | hs CRP, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Changes in plasmatic insulin | Insulin, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Changes in plasmatic Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) | HOMA-IR, assessed by enzymatic-colorimetric methods, with repeated measures (at the beginning and at the end of the intervention) | 0 and 6 weeks |
| Evaluation of the mediterranean diet adherence to measure quality of life | Mediterranean diet adherence screener (MEDAS) is used, consisting in 14 questions (each one 0 or 1 point, final score between 0 and 14). Results are ranged between 0-7 points (low adherence), 7-10 (moderate adherence), and 10-14 (high adherence). This is only evaluated at the beginning of the intervention. | 0 weeks |
| Evaluation of the physical activity to measure quality of life | International physical activity questionaire-short form (IPAC-SF) is used, consisting in 7 questions. Intensity, frequency and duration of the exercise are evaluated through metabolic equivalent of task (METs). This allows to differentiate 3 levels of physical activity: Low: Not enough activity to achieve the next level Moderate: 3 or more days of vigorous physical activity for at least 20 minutes per day, 5 or more days of moderate physical activity and/or walking at least 30 minutes per day, or 5 or more days of any combination of walking, moderate or vigorous physical activity achieving at least a total of 600 METs High: Vigorous physical activity at least 3 days per week achieving a total of at least 1500 METs, or 7 days of any combination of walking, with moderate and/or vigorous physical activity, achieving a total of at least 3000 METs This is only evaluated at the beginning of the intervention. | 0 weeks |
| Restivo I, Attanzio A, Tesoriere L, Allegra M, Garcia-Llatas G, Cilla A. Anti-Eryptotic Activity of Food-Derived Phytochemicals and Natural Compounds. Int J Mol Sci. 2022 Mar 11;23(6):3019. doi: 10.3390/ijms23063019. |
| 42374719 | Derived | Miedes D, Mercatante D, Broseta S, Cilla A, Rodriguez-Estrada MT, Alegria A. Effect of Plant Sterols on Cholesterol Oxidation Products in Statin-Treated Hypercholesterolemic Individuals: A Pilot Study. J Diet Suppl. 2026 Jun 29:1-16. doi: 10.1080/19390211.2026.2695120. Online ahead of print. |
| D009750 |
| Nutritional and Metabolic Diseases |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |